OCT 17, 2013 11:00 AM PDT

The Need for Critical Reassessment of Current Strategies for Cancer Therapeutics.

C.E. Credits: CE
Speaker

Abstract

Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant lesions. Cancer is a complex adaptive system. Tumor progression reflects the co-evolutionary dynamics of host-tumor interactions and the progressive selection of tumor clones of increasing fitness able to survive in varied host tissue microenvironments and to circumvent host defenses and therapeutic intervention. Improved success in confronting this intrinsic biological complexity requires major changes in current approaches to the discovery and clinical validation of new therapeutics. The following needs must be accorded higher priority. *new tools to map the dynamic topology of perturbed molecular signaling networks in malignancies arising in different cell lineages to better predict the compensatory pathways most likely to confer resistance to guide new drug development and as companion diagnostics for monitoring emergence of resistance *new approaches for therapeutic action at multiple targets in perturbed signaling networks via new combinations of targeted therapies or, more challenging, the design of promiscuous polypharmacology in a single agent *new minimally invasive blood-based diagnostics such as CTCs, ctDNA or exosomes for faster detection of resistance and agile changes in treatment regimens *new adaptive clinical trial protocols such as I-SPY for simultaneous evaluation of multiple agents and agile switching of agent combinations guided by biomarker profiling of response/resistance patterns. This will also require new regulatory paradigms to accommodate the increased statistical and logistical complexities of adaptive clinical trials and efficacy assessment of combinations of investigational agents and companion biomarkers *new value propositions for payors (and patients) linking reimbursement and pricing policies to more substantial improvements in clinical outcomes *new approaches for rapid updating of standard-of-care (SOC) guidelines and improved physician education to reflect advances in molecular oncology and greater adoption of routine molecular profiling of patients for improved therapy selection *new patient advocacy approaches to enhance patient education about the value of molecular profiling in treatment choice and increase the enrollment of eligible patients into investigational trials


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
MAY 18, 2021 7:00 AM PDT
MAY 18, 2021 7:00 AM PDT
Date: May 18, 2021 Time: 7:00am PDT, 10:00am EDT Proteins encoded by mutant genes in cancers can be processed and presented on tumor cell surface by human leukocyte antigen (HLA) molecules,...
OCT 17, 2013 11:00 AM PDT

The Need for Critical Reassessment of Current Strategies for Cancer Therapeutics.

C.E. Credits: CE

Specialty

Antibodies

Virology

Immunology

Dna Sequencing

Personalized Medicine

Clinical Diagnostics

Immunity

Cancer Diagnostics

Immunotherapy

Bioinformatics

Flow Cytometry

Immuno-Oncology

Gene Expression

Dna

Big Data

Geography

Europe100%

Registration Source

Website Visitors100%

Job Title

Student100%

Organization

Academic Institution100%


Show Resources
Loading Comments...
Show Resources